Local NHS patients contribute key data to practice-changing COVID-19 study
Date published: 02 September 2020
One research paper suggests the risk of death can be reduced by up to 20%
Patients, NHS trusts and local research teams across the Greater Manchester region have contributed important data to new global research which shows that corticosteroids can significantly improve outcomes for severely ill patients with COVID-19.
The research papers published in the Journal of the American Medical Association (JAMA) today reinforce evidence that these inexpensive and widely available drugs improve outcomes for the most critically ill patients with the disease.
One paper suggests the risk of death can be reduced by up to 20%.
The papers include findings from the National Institute for Health Research (NIHR) supported REMAP-CAP study, which is being conducted across 15 countries around the world and led in the UK from the NIHR Imperial Biomedical Research Centre.
Working closely together to help deliver rapid recruitment, NHS trusts and the NIHR’s Clinical Research Network (NIHR CRN), and research institutes from the devolved nations helped recruit 71% of all global study participants from right across the UK.
While the local NIHR Clinical Research Network for Greater Manchester enrolled a total of 34 participants to this vital, practice-changing study at NHS hospitals across the region.
The local recruiting hospitals were North Manchester General Hospital, Salford Royal, Royal Oldham Hospital, Royal Blackburn Hospital, Manchester Royal Infirmary, Wythenshawe Hospital and Stepping Hill Hospital.
The results from the REMAP-CAP trial show a high probability that among critically ill patients with COVID-19, treatment with a seven-day course of hydrocortisone improved outcomes such as survival and more rapid recovery, compared with no hydrocortisone treatment.
An additional paper, co-ordinated by the World Health Organisation (WHO) and led by researchers at the University of Bristol and the NIHR’s Bristol Biomedical Research Centre, provides a meta-analysis (evidence summary) of global steroid use across seven randomised controlled trials (RCTs) in 12 countries spanning five continents.
It also included data drawn from REMAP-CAP and the NIHR-funded RECOVERY trial, which has already shown that the steroid dexamethasone can be successfully used in treatment of moderate to severe Covid-19.
It concludes that corticosteroids can reduce the risk of death in the most ill patients by up to 20%.
Anthony Gordon, Professor of Anaesthesia and Critical Care at Imperial College London, and the study’s Chief Investigator, said: “The UK has been able to deliver so well in this study because of the joined up research processes that we have in this country.
"The NIHR provides infrastructure support to ensure research can be delivered efficiently throughout the whole NHS. This system is the envy of our international colleagues.”
NHS chief executive Sir Simon Stevens said: “One of the distinctive benefits of having our NHS is that we've been able to mobilise quickly and at scale to help researchers test and develop proven coronavirus treatments.
"Just as we did with dexamethasone, the NHS will now take immediate action to ensure that patients who could benefit from treatment with hydrocortisone do so, adding a further weapon in the armoury in the worldwide fight against Covid-19.”
Do you have a story for us? Want to tell us about something going on in and around Oldham? Let us know by emailing firstname.lastname@example.org , calling our Oldham-based newsroom on 0161 633 2121 , tweeting us @oldhamchronicle or messaging us through our Facebook page. All contact will be treated in confidence.
Most Viewed News Stories
- 1Covid breaches across Greater Manchester include weddings and "barber shops in garden sheds"
- 2‘Deserted’ 170-year-old mill to be demolished and replaced with shops and flats
- 3Extra Coronavirus testing processing arrives in Oldham
- 4Oldham trio charged following Op Foam raids
- 5‘Bizarre complaints’ over Covid-19 grants